Infant Bacterial Therapeutics AB (publ)の主要な財務諸表は何ですか?
IFTBFの主要な財務比率は何ですか?
Infant Bacterial Therapeutics AB (publ)の収益はセグメントまたは地域別にどのように分けられていますか?
Infant Bacterial Therapeutics AB (publ)は収益を上げていますか?
Infant Bacterial Therapeutics AB (publ)に負債はありますか?
Infant Bacterial Therapeutics AB (publ)の発行済株式数は何株ですか?
主要データ
前終値
$4.78
始値
$5.47
当日レンジ
$5.47 - $5.47
52週レンジ
$4.78 - $8.2
取引高
--
平均取引高
1.0K
1株当たり利益(TTM)
--
配当利回り
--
時価総額
--
INFANT BACTERIAL THERAPEUTICS Aとは何ですか?
Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.